IP Library Granted Patent US 10,358,633
Granted Patent B2
US 10,358,633 · App. 15/664,172 · Granted Jul 23, 2019

Method for producing an ActRIIB-Fc fusion polypeptide

Inventors: Jasbir Seehra (Lexington, MA); Ravindra Kumar (Acton, MA)
Assignee: ACCELERON PHARMA INC.
C12N9/12C07K14/475C07K14/71A61K38/00C07H21/04C07K2319/30C12N2510/02C12Y207/1103
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,358,633
App. No.
15/664,172
Granted
Jul 23, 2019
Kind
B2
Abstract

In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.

Claims (10)

1. A method for producing an ActRIIB-Fc fusion polypeptide, comprising:

a) culturing a host cell under conditions suitable for expression of the polypeptide, and

b) recovering the polypeptide expressed by the cell;

wherein the cell comprises a nucleic acid, wherein the nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 8.

2. The method of claim 1 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 4.

3. The method of claim 1 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 6.

4. The method of claim 3 , wherein the mammalian cell is a CHO cell.

5. The method of claim 1 , wherein the amino terminus of the polypeptide has the sequence ETR.

6. The method of claim 1 , wherein the host cell is a mammalian cell.

7. The method of claim 1 , wherein the nucleic acid is operably linked to one or more regulatory sequences.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2017
From: SEEHRA, JASBIR; KUMAR, RAVINDRA
To: ACCELERON PHARMA INC.
Reel/Frame 043775/0364 →
Continuity (6)
Continuation 14814040 · Jul 30, 2015
Continuation 13657649 · Oct 22, 2012
Division 12796307 · Jun 8, 2010
Provisional Application 61280543 · Nov 3, 2009
Provisional Application 61268420 · Jun 12, 2009
Related Publication 20180080012A1 · Mar 22, 2018
Cited By (7)
US 12,186,370 US 12,269,858 US 12,350,313 US 12,364,737 US 12,440,539 US 12,522,646 US 12,582,700